Central retinal vein occlusion: Difference between revisions

No edit summary
Line 1: Line 1:
==Background==
==Background==
*Risk Factors
[[File:Schematic diagram of the human eye en.png|thumb|Eye anatomy.]]
**[[Diabetes mellitus]]  
 
**[[Hypertension]]  
===Risk Factors===
**Hypercoagulable states  
*[[Diabetes mellitus]]  
**[[Vasculitis]]  
*[[Hypertension]]  
**[[Glaucoma]]
*Hypercoagulable states  
*[[Vasculitis]]  
*[[Glaucoma]]


[[File:crvo.png|thumbnail|CRVO Blood and Thunder]]
[[File:crvo.png|thumbnail|CRVO Blood and Thunder]]

Revision as of 20:58, 16 December 2020

Background

Eye anatomy.

Risk Factors

CRVO Blood and Thunder

Clinical Features

  • Loss of vision
    • Variable, ranging from vague blurring to rapid, painless monocular vision loss
  • Fundoscopy
    • Optic disc edema, dilated and tortuous veins, diffuse retinal hemorrhages ("blood-and-thunder fundus")

Differential Diagnosis

Acute Vision Loss (Noninflamed)

Emergent Diagnosis

Evaluation

Management

  • Consult ophtho and neuro
  • No treatment regimen provides significant and consistent results
  • Complex treatment possibly involving aspirin, anticoagulation, fibrinolysis, lowering IOP, topical steroids, cyclocryotherapy, photocoagulation, intravitreal injections (triamcinolone, anti-VEGF, aflibercept) while managing underlying medical diseases
  • Possible benefit from LMWH plus aspirin in central retinal vein occlusion[1]
    • May provide a 78% risk reduction of adverse ocular outcome in central vein occlusion
    • Less benefit in branched retinal vein occlusion

Disposition

See Also

Acute Vision Loss (Noninflamed)

References

  1. Lazo-Langner A et al. Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica. 2010 Sep; 95(9): 1587–1593.